Ramsay Stattman Vela & Price’s Biogen BIIB Stock Holding History

Ramsay Stattman Vela & Price’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,545	Closed	-$881K	–	77
2024 Q3	$881K	Sell	4,545 -3,000	-40%	-$628K	0.16%	62
2024 Q2	$1.75M	Hold	7,545	–	–	0.33%	50
2024 Q1	$1.63M	Hold	7,545	–	–	0.31%	51
2023 Q4	$1.95M	Sell	7,545 -75	-1%	-$18.4K	0.4%	49
2023 Q3	$1.96M	Hold	7,620	–	–	0.42%	48
2023 Q2	$2.17M	Hold	7,620	–	–	0.44%	48
2023 Q1	$2.12M	Hold	7,620	–	–	0.46%	49
2022 Q4	$2.11M	Hold	7,620	–	–	0.48%	49
2022 Q3	$2.04M	Sell	7,620 -1,275	-14%	-$271K	0.5%	50
2022 Q2	$1.81M	Buy	8,895 +745	+9%	+$152K	0.41%	54
2022 Q1	$1.72M	Buy	+8,150	New	+$1.77M	0.33%	58

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ramsay Stattman Vela & Price's BIIB Position: Q4 2024 in Review

Ramsay Stattman Vela & Price sold out of Biogen (BIIB) in Q4 2024, closing a stake of 4,545 shares — an estimated $881K sold.

Ramsay Stattman Vela & Price first reported a position in BIIB in Q1 2022 and held it in 11 quarters. The position peaked at $2.17M in Q2 2023. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Ramsay Stattman Vela & Price reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Ramsay Stattman Vela & Price sold 4,545 Biogen shares in Q4 2024, an estimated $881K.
Ramsay Stattman Vela & Price first reported a position in Biogen in Q1 2022 and held it in 11 quarters.
Ramsay Stattman Vela & Price's Biogen position peaked at $2.17M in Q2 2023.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Ramsay Stattman Vela & Price's 13F filing for Q4 2024, filed 31 Jan 2025.